Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines.

Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings per share during 2022.

Sanofi posts higher earnings and sales, sees further growth ahead

French healthcare group Sanofi's first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.

Sanofi operating income up 16% on bestseller drug Dupixent

Sanofi continues to deliver strong business EPS ( 1) growth driven by higher sales and improved margins in Q1

Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1

Emergent BioSolutions

Gilead Sciences

Eli Lilly

Merck

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Sanofi (SNY) Ahead of Earnings?

Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company's ambition to attain world-class standards of manufacturing excellence. Following a successful pilot in 2021 with McLaren Racing, both companies have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines, across all technologies. Learnings from this partnership will provide insights and develop best practices for manufacturing that will then be implemented across Sanofi's global industrial network .

Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence

Collaboration Supports Companies' Joint Focus on Medication Adherence and Affordability SAN FRANCISCO , April 13, 2022 /PRNewswire/ -- Today, Sempre Health announced compelling outcomes achieved during the first year of its collaboration with Sanofi (Nasdaq: SNY), an innovative global healthcare company. The results coming out of this collaboration have already led to health plans expanding their Sempre programs for 2022-2023.

Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi Medications

The Company's shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 3, 2022 at 2:30 p.m. (CET) at Paris Expo Porte de Versailles – 1, Place de la Porte de Versailles, Hall 5.1 – 75015 Paris.

Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents

The pharma giant recently shared encouraging results from a late-stage clinical trial for its hemophilia drug candidate.

Could This Drug Candidate Be a Blockbuster for Sanofi?

Regeneron Pharmaceuticals

Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.

Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

Sanofi's DE&I strategy was revamped in June 2021 with set objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can bring their whole selves and engaging with the company's diverse communities. The DE&I Board's role is to ensure Sanofi's DE&I strategy is rightly executed, to monitor progress on the company's 2025 targets and to advise on how to accelerate the company's impact in this space.

Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board

Sanofi expects to list its drug ingredients business EUROAPI on May 6, having received approval from French stock market regulator, the pharmaceutical giant said on Friday.

Sanofi to list drug ingredients business on May 6

Sanofi announced today that the French Autorité des marchés financiers (AMF) has approved the listing prospectus prepared by EUROAPI

Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022

IGM Biosciences Inc

A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.

Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals

French healthcare group Sanofi said it had priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).

France's Sanofi offers 1.5 billion euro bond linked to access to medicine

Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines

IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.

IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi

Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against three oncology targets and three immunology/inflammation targets. IGM will receive a $150 million upfront payment.

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi

Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets

Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets

French healthcare group Sanofi, which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion).

Healthcare group Sanofi targets Dupixent peak sales of over 13 billion euros

First Trust Nasdaq Pharmaceuticals ETF 

GlaxoSmithKline

Johnson & Johnson

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

French drugmaker Sanofi on Wednesday said it would stop immediately any new spending not related to the supply of essential and life-changing medicines and vaccines in Russia, as well as in Belarus.

News for Sanofi Stock (SNY)